# OnCo record her2-mutation (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/her2-mutation/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "her2-mutation" ;
  schema:name "HER2 (ERBB2) activating mutation"@en ;
  schema:alternateName "HER2 mutation"@en, "ERBB2 mutation"@en, "HER2-mutant NSCLC"@en, "ERBB2 exon 20 insertion"@en, "HER2 tyrosine kinase domain mutation"@en, "HER2 YVMA insertion"@en, "HER2 TKD mutation"@en ;
  schema:description "A HER2 mutation is a change in the gene's kinase domain, most often an exon 20 insertion, found in about 2 to 3 percent of lung adenocarcinomas. It is a different thing from HER2 amplification or overexpression, and it selects trastuzumab deruxtecan and, since 2025, zongertinib in lung cancer."@en ;
  schema:url <https://onco.cc/biomarkers/her2-mutation/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3fabf12-354e-4e5c-b5de-20fdb579b783> ;
  onco:tag "biomarker", "her2" ;
  onco:related <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/egfr-exon-20-insertion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/guardant360-cdx/> ;
  onco:terms <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/egfr-exon20-insertion/> .